COVID-19 Latest Updates and Resources

COVID-19 Vaccine General Update—March 4, 2021

By: Sam Cohen
< 1 Minute Read

Last week, the FDA approved the Johnson & Johnson (Janssen) vaccine under emergency use authorization (EUA), allowing it to join Pfizer and Moderna as the third vaccine available in the U.S. for the prevention of COVID-19. This week, vials of the new single-dose vaccine (the first single-dose vaccine available in the U.S.) have been shipped across the nation to further aid in the fight against the spread of COVID.

COVID-19 vaccines were first approved for distribution in the U.S. in December 2020, and early projections set a goal of 20 million vaccines administered by the year’s end. However, that goal was not met, with just over 2 million vaccines administered by the end of December. While there were delays during this initial rollout, many states are now catching up. As of March 3, 2021, 78.6 million vaccines have been administered to high-risk populations throughout the country, with providers now administering more than 2 million vaccine doses each day. States will continue to make decisions about which populations to prioritize and when individuals will be eligible to receive the vaccine, so it’s important to watch for local guidance as the vaccination initiative evolves.

To aid in the administration of vaccines to eligible individuals, Curi has developed comprehensive vaccination resources, including informed consent forms for both single-dose and two-dose vaccines and FAQs about their administration, with up-to-date, detailed information about the Pfizer, Moderna, and Janssen vaccines—all publicly available on our dedicated COVID-19 Command Center.

If you have specific questions regarding the administration of any of the approved COVID-19 vaccines, please feel free to contact one of our risk management experts at 800-662-7917.

Sam Cohen
Sam Cohen is Curi’s Senior Vice President of Health Policy. Curi members may contact him directly at sam.cohen@curi.com and 919.878.7602. Readers also can follow him on Twitter @samuel_c_cohen.
News & Knowledge